NCT00355628

Clinical Study of KW-2246 in Patients With Cancer Pain

Phase II Clinical Study of KW-2246 in Patients With Cancer Pain - Maintenance Switch Study in Oral Morphine or Oral Oxycodone-treated Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Kyowa Kirin Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a Phase II open-label study to investigate the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients.

Detailed description

This study is a Phase II open-label study to investigate, using the continual reassessment method procedure by pain intensity and safety as indicators, the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients who have been maintained on oral morphine or oral oxycodone for pain and to evaluate the safety and efficacy of KW-2246.

Conditions

• Pain
• Cancer

Interventions

Type	Name	Description
DRUG	KW-2246 (fentanyl citrate)	KW-2246

Timeline

• Start date: 2006-07-01
• Primary completion: 2007-07-01
• First posted: 2006-07-24
• Last updated: 2012-08-31

Locations

1 site across 1 country: Japan